Locatelli Francesco, Del Vecchio Lucia, Pozzoni Pietro, Manzoni Celestina
Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy.
J Nephrol. 2006 Jan-Feb;19(1):6-11.
Modern nephrology has become one of the liveliest and most productive branches of medicine. Once seen as a temporary means of rescue from uremic coma, hemodialysis (HD) has allowed thousands of people with irreversible uremia to survive for many years, and evolving treatment modalities have led to a significant increase in efficacy and tolerability. At the same time, two other forms of renal replacement therapy (RRT) have been developed: peritoneal dialysis (PD) and renal transplantation. The number of end-stage renal disease (ESRD) patients requiring RRT has increased dramatically throughout the world for a number of reasons: the improved survival of patients affected by other diseases, a real increase in the incidence of chronic kidney disease (CKD) mainly due to the burden of 'metabolic syndrome', and the significant broadening of RRT acceptance criteria. This last factor means that RRT has become available to increasing numbers of elderly patients, diabetics and patients with other severe comorbidities, among whom the leading cause of death is cardiovascular disease (CVD). However, nephrology is not just a case of substituting the function of failing kidneys; it also covers the treatment of glomerular diseases, slowing down CKD progression and managing the related comorbidities, all of which have substantially improved over the last 40 yrs.
现代肾脏病学已成为医学领域最活跃、成果最丰硕的分支之一。血液透析(HD)曾被视为从尿毒症昏迷中临时抢救的手段,如今却使成千上万患有不可逆性尿毒症的患者存活多年,而且不断发展的治疗方式已使疗效和耐受性显著提高。与此同时,另外两种肾脏替代疗法(RRT)也已得到发展:腹膜透析(PD)和肾移植。由于多种原因,全球范围内需要RRT的终末期肾病(ESRD)患者数量急剧增加:其他疾病患者的存活率提高,慢性肾脏病(CKD)发病率实际上升,主要归因于“代谢综合征”的负担,以及RRT接受标准的显著放宽。最后这一因素意味着越来越多的老年患者、糖尿病患者和患有其他严重合并症的患者能够接受RRT治疗,而这些患者的主要死因是心血管疾病(CVD)。然而,肾脏病学不仅仅是替代衰竭肾脏的功能;它还涵盖肾小球疾病的治疗、减缓CKD进展以及管理相关合并症,在过去40年里,所有这些方面都有了实质性改善。